MVASI vs XALKORI

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 17, 2026·How we rate

Possible drug interaction. MVASI and XALKORI are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	MVASI	XALKORI
Rating	72/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	BEVACIZUMAB-AWWB	CRIZOTINIB
Manufacturer	Amgen Inc	Pf Prism Cv
Dosage forms	Injectable	Capsule, Oral pellets
Drug class	—	—
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms	Non-Small-Cell Lung Carcinoma

mvasi xalkori

Rating

72/100

New

Pharmacy pays

—

Type

Active ingredient

BEVACIZUMAB-AWWB

CRIZOTINIB

Manufacturer

Amgen Inc

Pf Prism Cv

Dosage forms

Injectable

Capsule, Oral pellets

Drug class

—

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms

Non-Small-Cell Lung Carcinoma

Frequently asked questions

What is the difference between Mvasi and Xalkori?

Mvasi contains Bevacizumab-Awwb, while Xalkori contains Crizotinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.